Minimal Residual Disease Market
完整報告名稱與涵蓋範圍
Minimal Residual Disease Market, Share & Trends Analysis Report, By Product (Assay Kits & Reagents, Instruments), By Technology (Polymerase Chain Reaction, Next-Generation Sequencing, Flow Cytometry, Other Technologies), By Application (Hematological Malignancies, Lymphoma, Solid Tumors, Multiple Myeloma, Other Applications), By End User, By Region, and Segment Forecasts, 2025-2034
報告摘要
The worldwide Minimal Residual Disease Market stood at USD 1.4 Bn in 2024, and is expected to reach USD 4.6 Bn by 2034, recording a CAGR of 12.8% from 2025 through 2034.
At its core, Minimal Residual Disease pertains to key industry insights & findings from the report:
Precision oncology, which tailors cancer treatment to the molecular characteristics of an individual's cancer, represents a key driver of the mrd market. Stakeholders across the healthcare landscape are risingly turning to these solutions to meet contemporary demands.
Several factors contribute to this trajectory, including heightened call for next-generation products, expanding applications across diverse end-use sectors, and supportive government initiatives.
The market landscape is structured across several key segments—spanning type, application, distribution channel, and region—each contributing uniquely to overall market expansion.
Regional dynamics show North America and Europe as established hubs, with the Asia-Pacific region expected to deliver the strongest growth trajectory through the forecast period, fueled by demographic shifts and policy support.
Competition in this space is characterized by active product development, strategic collaborations, and geographic expansion among both global leaders and specialized niche players.
Through rigorous analysis of market trends, growth catalysts, restraints, and opportunities, this study offers valuable perspectives for companies, investors, and policymakers navigating this evolving landscape.
授權報價
| Single User PDF | $4,500 USD |
| Global Site License PDF | $9,500 USD |
目錄 Table of Contents
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global Minimal Residual Disease Market Snapshot
Chapter 4. Global Minimal Residual Disease Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Investment and Funding Analysis
4.6. Porter's Five Forces Analysis
4.7. Incremental Opportunity Analysis (US$ MN), 2024-2034
4.8. Competitive Landscape & Market Share Analysis, By Key Player (2023)
4.9. Use/impact of AI on Minimal Residual Disease Market Industry Trends
4.10. Global Minimal Residual Disease Market Penetration & Growth Prospect Mapping (US$ Mn), 2021-2034
Chapter 5. Minimal Residual Disease Market Segmentation 1: By Product, Estimates & Trend Analysis
5.1. Market Share by Product, 2024 & 2034
5.2. Market Size Revenue (US$ Million) & Forecasts and Trend Analyses, 2021 to 2034 for the following Product:
5.2.1. Assay Kits & Reagents
5.2.2. Instruments
Chapter 6. Minimal Residual Disease Market Segmentation 2: By Technology, Estimates & Trend Analysis
6.1. Market Share by Technology, 2024 & 2034
6.2. Market Size Revenue (US$ Million) & Forecasts and Trend Analyses, 2021 to 2034 for the following Technology:
6.2.1. Polymerase Chain Reaction
6.2.2. Next-Generation Sequencing
6.2.3. Flow Cytometry
6.2.4. Other Technologies
Chapter 7. Minimal Residual Disease Market Segmentation 3: By Application, Estimates & Trend Analysis
7.1. Market Share by Application, 2024 & 2034
7.2. Market Size Revenue (US$ Million) & Forecasts and Trend Analyses, 2021 to 2034 for the following Application:
7.2.1. Hematological Malignancies
7.2.1.1. Leukemia
7.2.1.1.1. Myeloid Leukemia
7.2.1.1.2. Lymphocytic Leukemia
7.2.1.1.3. Other Leukemias
7.2.1.2. Lymphoma
7.2.1.2.1. Non-Hodgkin Lymphoma
7.2.1.2.2. Hodgkin Lymphoma
7.2.2. Solid Tumors
7.2.3. Multiple Myeloma
7.2.4. Other Applications
Chapter 8. Minimal Residual Disease Market Segmentation 3: By End User, Estimates & Trend Analysis
8.1. Market Share by End User, 2024 & 2034
8.2. Market Size Revenue (US$ Million) & Forecasts and Trend Analyses, 2021 to 2034 for the following End User:
8.2.1. Hospitals & Specialty Clinics
8.2.2. Diagnostic Laboratories
8.2.3. Academic & Research Institutes
8.2.4. Other End Users
Chapter 9. Minimal Residual Disease Market Segmentation 5: Regional Estimates & Trend Analysis
9.1. Global Minimal Residual Disease Market, Regional Snapshot 2024 & 2034
9.2. North America
9.2.1. North America Minimal Residual Disease Market Revenue (US$ Million) Estimates and Forecasts by Country, 2021-2034
9.2.1.1. US
9.2.1.2. Canada
9.2.2. North America Minimal Residual Disease Market Revenue (US$ Million) Estimates and Forecasts by Product, 2021-2034
9.2.3. North America Minimal Residual Disease Market Revenue (US$ Million) Estimates and Forecasts by Technology, 2021-2034
9.2.4. North America Minimal Residual Disease Market Revenue (US$ Million) Estimates and Forecasts by Application, 2021-2034
9.2.5. North America Minimal Residual Disease Market Revenue (US$ Million) Estimates and Forecasts by End User, 2021-2034
9.3. Europe
9.3.1. Europe Minimal Residual Disease Market Revenue (US$ Million) Estimates and Forecasts by Country, 2021-2034
9.3.1.1. Germany
9.3.1.2. U.K.
9.3.1.3. France
9.3.1.4. Italy
9.3.1.5. Spain
9.3.1.6. Rest of Europe
9.3.2. Europe Minimal Residual Disease Market Revenue (US$ Million) Estimates and Forecasts by Product, 2021-2034
9.3.3. Europe Minimal Residual Disease Market Revenue (US$ Million) Estimates and Forecasts by Technology, 2021-2034
9.3.4. Europe Minimal Residual Disease Market Revenue (US$ Million) Estimates and Forecasts by Application, 2021-2034
9.3.5. Europe Minimal Residual Disease Market Revenue (US$ Million) Estimates and Forecasts by End User, 2021-2034
9.4. Asia Pacific
9.4.1. Asia Pacific Minimal Residual Disease Market Revenue (US$ Million) Estimates and Forecasts by Country, 2021-2034
9.4.1.1. India
9.4.1.2. China
9.4.1.3. Japan
9.4.1.4. Australia
9.4.1.5. South Korea
9.4.1.6. Hong Kong
9.4.1.7. Southeast Asia
9.4.1.8. Rest of Asia Pacific
9.4.2. Asia Pacific Minimal Residual Disease Market Revenue (US$ Million) Estimates and Forecasts by Product, 2021-2034
9.4.3. Asia Pacific Minimal Residual Disease Market Revenue (US$ Million) Estimates and Forecasts by Technology, 2021-2034
9.4.4. Asia Pacific Minimal Residual Disease Market Revenue (US$ Million) Estimates and Forecasts by Application, 2021-2034
9.4.5. Asia Pacific Minimal Residual Disease Market Revenue (US$ Million) Estimates and Forecasts by End User, 2021-2034
9.5. Latin America
9.5.1. Latin America Minimal Residual Disease Market Revenue (US$ Million) Estimates and Forecasts by Country, 2021-2034
9.5.1.1. Brazil
9.5.1.2. Mexico
9.5.1.3. Rest of Latin America
9.5.2. Latin America Minimal Residual Disease Market Revenue (US$ Million) Estimates and Forecasts by Product, 2021-2034
9.5.3. Latin America Minimal Residual Disease Market Revenue (US$ Million) Estimates and Forecasts by Technology, 2021-2034
9.5.4. Latin America Minimal Residual Disease Market Revenue (US$ Million) Estimates and Forecasts by Application, 2021-2034
9.5.5. Latin America Minimal Residual Disease Market Revenue (US$ Million) Estimates and Forecasts by End User, 2021-2034
9.6. Middle East & Africa
9.6.1. Middle East & Africa Wind Turbine Rotor Blade Market Revenue (US$ Million) Estimates and Forecasts by country, 2021-2034
9.6.1.1. GCC Countries
9.6.1.2. Israel
9.6.1.3. South Africa
9.6.1.4. Rest of Middle East and Africa
9.6.2. Middle East & Africa Minimal Residual Disease Market Revenue (US$ Million) Estimates and Forecasts by Product, 2021-2034
9.6.3. Middle East & Africa Minimal Residual Disease Market Revenue (US$ Million) Estimates and Forecasts by Technology, 2021-2034
9.6.4. Middle East & Africa Minimal Residual Disease Market Revenue (US$ Million) Estimates and Forecasts by Application, 2021-2034
9.6.5. Middle East & Africa Minimal Residual Disease Market Revenue (US$ Million) Estimates and Forecasts by End User, 2021-2034
Chapter 10. Competitive Landscape
10.1. Major Mergers and Acquisitions/Strategic Alliances
10.2. Company Profiles
10.2.1. F. Hoffmann-La Roche Ag
10.2.1.1. Business Overview
10.2.1.2. Key Product/Service Overview
10.2.1.3. Financial Performance
10.2.1.4. Geographical Presence
10.2.1.5. Recent Developments with Business Strategy
10.2.2. Laboratory Corporation Of America Holdings
10.2.3. Guardant Health, Inc.
10.2.4. Sysmex Corporation
10.2.5. NEOGENOMICS Laboratories
10.2.6. MOLECULARMD (A Subsidiary Of Icon Plc)
10.2.7. Adaptive Biotechnologies
10.2.8. ARCHERDX (Invitae Corporation)
10.2.9. Bio-Rad Laboratories, Inc.
10.2.10. Natera, Inc.
10.2.11. OPKO Health, Inc.
10.2.12. GENETRON Health
10.2.13. Quest Diagnostics, Inc.
10.2.14. ASURAGEN, Inc.
10.2.15. INVIVOSCRIBE, Inc.
10.2.16. Arup Laboratories Inc.
10.2.17. Mission Bio, Inc.
10.2.18. CERGENTIS B.V.
常見問題
這份報告可以先索取樣本嗎？
可以。建議購買前先申請樣本，提出申請後約 2 個工作天內提供，您可以先確認內容涵蓋範圍是否符合需求。
報告價格如何計算？
報告以美元標價，台幣報價依當日匯率換算並加計 5% 營業稅。不同授權版本（單人／多人／企業全站）價格不同，量子訊息會評估您的使用情境後提供最優惠報價。
下單後多久交付？如何付款？
一般 3–7 個工作天交付，實際依出版商狀況於下單前確認。收到報告確認無誤後開立台幣發票，30 天內電匯付款即可。
量子訊息有限公司為 InsightAce Analytic 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們